SION · Sionna Therapeutics, Inc. · Analyst Estimates
$3.87
+0.18 (+4.88%)
At close · Oct 27
Return incl. dividend (before tax)
Q2 2026 earnings call transcript
Going-concern doubt
— cleared Aug 6, 2026
The latest filing states the doubt was alleviated.
“The Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are issued. The Company believes that its existing cash, cash equivalents and marketable securities of $268.3 million as of June 30, 2026, will be sufficient to allow the Company to fund operations beyond twelve months from the date that the financial statements are issued.”View the 10-Q filed Aug 6, 2026
Market Cap
$165.93M
Shares
45.21M
Volume · Oct 27
1M
Avg daily vol (3M)
2.25M
Analyst Estimates
Compare analyst forecasts for Sionna Therapeutics, Inc. across metrics and forecast periods.
Estimates are grouped by forecast period, with low, average and high together. A dash means that statistic is not available.
Compiled consensus
These figures are a compiled consensus of analyst forecasts, not a survey the company published itself. Every figure is the statistic the source states; averages are means, never medians.
Captured 2026-10-07 05:50 UTC · Publication dates shown per estimate · 8 metric / period groups
FY ending 2026-12-31
| Metric | Low | Average | High | Analyst count | Average, 7 days ago | Average, 30 days ago | Average, 60 days ago | Average, 90 days ago | Estimates lowered, last 7 days | Estimates lowered, last 30 days | Estimates raised, last 7 days | Estimates raised, last 30 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EPS
USD
Publication date not stated |
-2.64
|
-2.45
|
-1.93
|
10
|
-2.56
|
-2.56
|
-2.54
|
-2.54
|
1
|
1
|
2
|
2
|
|
Revenue
USD
Publication date not stated |
0.00
|
0.00
|
0.00
|
10
|
— | — | — | — | — | — | — | — |
FY ending 2027-12-31
| Metric | Low | Average | High | Analyst count | Average, 7 days ago | Average, 30 days ago | Average, 60 days ago | Average, 90 days ago | Estimates lowered, last 7 days | Estimates lowered, last 30 days | Estimates raised, last 7 days | Estimates raised, last 30 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EPS
USD
Publication date not stated |
-3.18
|
-2.23
|
-1.24
|
10
|
-2.53
|
-2.53
|
-2.80
|
-2.80
|
0
|
0
|
3
|
3
|
|
Revenue
USD
Publication date not stated |
0.00
|
0.00
|
0.00
|
10
|
— | — | — | — | — | — | — | — |
Q ending 2026-09-30
| Metric | Low | Average | High | Analyst count | Average, 7 days ago | Average, 30 days ago | Average, 60 days ago | Average, 90 days ago | Estimates lowered, last 7 days | Estimates lowered, last 30 days | Estimates raised, last 7 days | Estimates raised, last 30 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EPS
USD
Publication date not stated |
-0.84
|
-0.68
|
-0.53
|
8
|
-0.67
|
-0.67
|
-0.65
|
-0.65
|
1
|
1
|
2
|
2
|
|
Revenue
USD
Publication date not stated |
0.00
|
0.00
|
0.00
|
10
|
— | — | — | — | — | — | — | — |
Q ending 2026-12-31
| Metric | Low | Average | High | Analyst count | Average, 7 days ago | Average, 30 days ago | Average, 60 days ago | Average, 90 days ago | Estimates lowered, last 7 days | Estimates lowered, last 30 days | Estimates raised, last 7 days | Estimates raised, last 30 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EPS
USD
Publication date not stated |
-0.68
|
-0.55
|
-0.37
|
8
|
-0.62
|
-0.62
|
-0.66
|
-0.66
|
0
|
0
|
3
|
3
|
|
Revenue
USD
Publication date not stated |
0.00
|
0.00
|
0.00
|
10
|
— | — | — | — | — | — | — | — |
Key facts
CIK
2036042
CUSIP
829401108
13F (30d)
16 filings
16 filers
Visit website
Investor relations